Progress in Corporate MattersThe Company added a highly respected pharma industry veteran, Dr. Guenter Rosskamp, to its management team as CEO of the Company's German subsidiary. Dr. Rosskamp previously served for many years as Head of Central Nervous System Therapeutics, and as head of Strategic Business Development, for Schering AG (now part of Bayer AG). In those capacities, Dr. Rosskamp was responsible for the development and commercialization of multiple drugs.
The Company expanded its Board in 2012 with highly two respected experts: Dr. Navid Malik and Mr. Jerry Jasinowski. Dr. Malik is Head of Life Sciences Research for Cenkos Securities Plc. in the UK, and has been one of the most influential analysts in the UK and Europe over the last decade, covering the life sciences industry worldwide. Mr. Jasinowski is a nationally recognized chief executive who headed up the largest industrial trade association in the US (the National Association of Manufacturers) for fourteen years, and has extensive board experience across a wide range of manufacturing, technology, and financial firms, including Fortune 1000 and Fortune 500 companies.
Progress in Intellectual Property – PatentsA dozen new patents were issued to the Company in 2012 as part of its worldwide patent portfolio of over 180 issued and pending patents. The newly issued patents covered a variety of subject matter, such as the proprietary partial maturation for DCVax-Direct, the machines and systems to manufacture DCVax-Direct, processes for enhancing the potency of dendritic cells in general, measures of product quality, and other.
Progress in FinancingDuring 2012, the Company completed a comprehensive clean-up of its balance sheet, through which it removed the vast majority of all investor debt. The Company continued to carry trade payable
|SOURCE Northwest Biotherapeutics|
Copyright©2012 PR Newswire.
All rights reserved